Immutep’s efti drug to be evaluated against COVID-19

• Immutep's (NASDAQ:IMMP) has announced that its cancer therapy eftilagimod alpha (efti or IMP321) will be tested in an investigator-initiated trial against COVID-19.
• The Phase 2 trial will evaluate efti in up to 110 patients hospitalized with COVID-19, with primary endpoint is the patient’s clinical status at day 15.
• Under the agreement, Immutep will provide efti at no cost to the University Hospital Pilsen, while the hospital will fund the study. All necessary approvals from the Czech Republic authorities have been received, so the hospital can start immediate recruitment.
• Recruitment will start with an open label safety run-in of six patients, followed by a first cohort of 26 randomized patients. Successive cohorts will be recruited following positive recommendations from the Data Monitoring Committee, which will evaluate safety and efficacy of the treatment
• Efti is an antigen-presenting cell activator, and works to stimulate the body's immune response by boosting CD8 effector T cells.
• https://seekingalpha.com/news/3625326-immutep-s-efti-drug-to-be-evaluated-against-covidminus-19